Rhumbline Advisers Decreases Stake in Halozyme Therapeutics, Inc. $HALO

Rhumbline Advisers decreased its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 4.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 364,162 shares of the biopharmaceutical company’s stock after selling 17,487 shares during the period. Rhumbline Advisers’ holdings in Halozyme Therapeutics were worth $26,708,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of HALO. Campbell Newman Asset Management Inc. lifted its stake in Halozyme Therapeutics by 0.4% in the 3rd quarter. Campbell Newman Asset Management Inc. now owns 36,878 shares of the biopharmaceutical company’s stock valued at $2,705,000 after buying an additional 153 shares in the last quarter. Alps Advisors Inc. grew its holdings in Halozyme Therapeutics by 3.0% in the 3rd quarter. Alps Advisors Inc. now owns 5,926 shares of the biopharmaceutical company’s stock valued at $435,000 after buying an additional 170 shares during the period. EverSource Wealth Advisors LLC grew its position in Halozyme Therapeutics by 6.9% during the second quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company’s stock valued at $140,000 after acquiring an additional 174 shares during the period. Richardson Financial Services Inc. raised its holdings in shares of Halozyme Therapeutics by 87.6% in the 3rd quarter. Richardson Financial Services Inc. now owns 424 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 198 shares during the period. Finally, Brown Advisory Inc. lifted its stake in shares of Halozyme Therapeutics by 0.6% in the 2nd quarter. Brown Advisory Inc. now owns 35,057 shares of the biopharmaceutical company’s stock valued at $1,824,000 after purchasing an additional 224 shares in the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock.

Halozyme Therapeutics Trading Up 3.3%

NASDAQ:HALO opened at $79.44 on Monday. The stock has a market cap of $9.34 billion, a price-to-earnings ratio of 16.72, a PEG ratio of 0.33 and a beta of 0.97. The company has a debt-to-equity ratio of 1.59, a quick ratio of 1.37 and a current ratio of 1.59. The business has a fifty day moving average of $70.85 and a 200-day moving average of $69.96. Halozyme Therapeutics, Inc. has a 1 year low of $47.50 and a 1 year high of $82.22.

Insider Activity

In related news, Director Bernadette Connaughton sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $70.25, for a total value of $140,500.00. Following the sale, the director directly owned 40,123 shares in the company, valued at $2,818,640.75. The trade was a 4.75% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Helen Torley sold 10,000 shares of the business’s stock in a transaction on Thursday, February 5th. The stock was sold at an average price of $78.64, for a total value of $786,400.00. Following the sale, the chief executive officer directly owned 708,719 shares in the company, valued at $55,733,662.16. This trade represents a 1.39% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 49,398 shares of company stock worth $3,650,592. 2.90% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on HALO. TD Cowen boosted their price objective on Halozyme Therapeutics from $79.00 to $90.00 and gave the stock a “buy” rating in a research note on Thursday, January 8th. Benchmark restated a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, February 3rd. The Goldman Sachs Group reaffirmed a “sell” rating and issued a $56.00 price target on shares of Halozyme Therapeutics in a report on Thursday, December 4th. HC Wainwright restated a “buy” rating on shares of Halozyme Therapeutics in a research note on Thursday, January 29th. Finally, Citizens Jmp upped their price objective on Halozyme Therapeutics from $91.00 to $92.00 and gave the company a “market outperform” rating in a research note on Tuesday, November 4th. Eight research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Halozyme Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $78.80.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.